Zentalis Pharmaceuticals, Inc. Shares Rise After Trial Data Release
Photo: TokenPost
Zentalis Pharmaceuticals, Inc. shares rose Monday, Oct. 19, after the company released interim Phase 2 data on Sunday showing 15.8 months of median overall survival in a Cyclin E1-positive subgroup with platinum-resistant ovarian cancer. Median overall survival was 15.8 months for 48 patients whose tumors tested positive for Cyclin E1, compared with 7.5 months for 46 patients who tested negative. Both groups received azenosertib alone. Overall survival was a secondary endpoint, and the analysis included data collected through Sept. 2, 2025. The study enrolled 102 patients who had received one to five prior lines of treatment.
Source: TokenPost
